Skip to content

Inspection Record

Shilpa Medicare Limited — FDA 483 Findings

US FDAInspected 2026-05-29Published 2026-10-22 5 findingsEquipment and facilityComputer system validationDeviation, CAPA, and investigationProcess validationOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

You established for Clean Hold Time (CHT) and Dirty Hold Time Study (DHT) for the following shared equipment (non-dedicated) that is used to manufacture : which was not based on the worst-case molecules.

2Computer system validation

Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

3Deviation, CAPA, and investigation

Written records are not always made of investigations into unexplained discrepancies.

4Process validation

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

5Other quality system

Production records do not contain complete information relating to the production and control of each batch.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-22. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Shilpa Medicare Limited findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.